Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14605490 | 1.00 | NR1H4 (0.85) | NR1H4HSD17B13 | |
| SCHEMBL14562396 | 1.00 | NR1H4 (0.85) | NR1H4HSD17B13 | |
| SCHEMBL19620249 | 0.94 | NR1H4 (0.74) | NR1H4HSD17B13 | |
| SCHEMBL29881197 | 0.92 | NR1H4 (1.00) | NR1H4HSD17B13 | |
| SCHEMBL14605221 | 0.92 | NR1H4 (1.00) | NR1H4HSD17B13 | |
| SCHEMBL14785047 | 0.92 | NR1H4 (1.00) | NR1H4HSD17B13 | |
| SCHEMBL14562448 | 0.92 | NR1H4 (1.00) | NR1H4HSD17B13 | |
| SCHEMBL19202439 | 0.91 | NR1H4 (0.85) | NR1H4HSD17B13 | |
| SCHEMBL19202181 | 0.91 | NR1H4 (0.75) | NR1H4HSD17B13 | |
| SCHEMBL14641906 | 0.89 | NR1H4 (0.79) | NR1H4HSD17B13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4400503-A2 | NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2024-07-17 | — | — | EP | disclosed |
| CN-107252424-B | Novel FXR (NR1H4) binding and activity modulating compounds | 吉尔利德科学股份有限公司 | 2020-03-27 | — | — | CN | disclosed |
| US-20190142814-A1 | Novel FXR (NR1H4) binding and activity modulating compounds | PHENEX PHARMACEUTICALS AG (DE) | 2019-05-16 | — | — | US | disclosed |
| US-10220027-B2 | FXR (NR1H4) binding and activity modulating compounds | GILEAD SCIENCES, INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-20180200243-A1 | Novel FXR (NR1H4) binding and activity modulating compounds | PHENEX PHARMACEUTICALS AG (DE) | 2018-07-19 | — | — | US | disclosed |
| US-20180200243-A1 | Novel FXR (NR1H4) binding and activity modulating compounds | PHENEX PHARMACEUTICALS AG (DE) | 2018-07-19 | — | — | US | disclosed |
| EP-3246070-A1 | NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING AZOLES | Gilead Sciences, Inc. (US) | 2017-11-22 | — | — | EP | disclosed |
| US-9820979-B2 | FXR (NR1H4) binding and activity modulating compounds | GILEAD SCIENCES, INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-9820979-B2 | FXR (NR1H4) binding and activity modulating compounds | GILEAD SCIENCES, INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-20170143684-A1 | NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2017-05-25 | — | — | US | disclosed |
| EP-2987532-B1 | NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2017-04-12 | — | — | EP | disclosed |
| US-9539244-B2 | FXR (NR1H4) binding and activity modulating compounds | GILEAD SCIENCES, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-9539244-B2 | FXR (NR1H4) binding and activity modulating compounds | GILEAD SCIENCES, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| EP-2731676-B1 | NOVEL FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2016-02-03 | — | — | EP | disclosed |
| US-20150342930-A1 | NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2015-12-03 | — | — | US | disclosed |
| US-20150342930-A1 | NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2015-12-03 | — | — | US | disclosed |
| US-9139539-B2 | FXR (NR1H4) binding and activity modulating compounds | GILEAD SCIENCES, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9139539-B2 | FXR (NR1H4) binding and activity modulating compounds | GILEAD SCIENCES, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20140221659-A1 | NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2014-08-07 | — | — | US | disclosed |
| US-20140221659-A1 | NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2014-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180200243-A1 | Novel FXR (NR1H4) binding and activity modulating compounds | NR1H4, NR1H2, NR1H3 | NR1H4 1/4885HSD17B13 430/4885 |
| US-10220027-B2 | FXR (NR1H4) binding and activity modulating compounds | NR1H4, NR1H2, NR1H3 | NR1H4 1/4885HSD17B13 360/4885 |
| US-20150342930-A1 | NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | NR1H4 1/4885HSD17B13 430/4885 |
| US-20170143684-A1 | NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | NR1H4 1/4885HSD17B13 430/4885 |
| US-20190142814-A1 | Novel FXR (NR1H4) binding and activity modulating compounds | NR1H4, NR1H2, NR1H3 | NR1H4 1/4885HSD17B13 430/4885 |
| US-20140221659-A1 | NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | NR1H4 1/4885HSD17B13 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.